Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eloxx Pharmaceuticals, Inc. (ELOX)
USD12.59
+1.33 (+11.81%)
US OTC Healthcare Biotechnology
Address
480 Arsenal Way 2472
Watertown, MA, US
Watertown, MA, US
CEO
Sumit Aggarwal
Website
eloxxpharma.com
IPO
1999-04-26
CIK 1035354 ISIN US29014R3012
Description
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.59
+1.33 (+11.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
62.1K
Beta
-24.60
Float Shares
3.20M
Free Float %
97.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.78% | +2.78% | +94.74% | +369,900.01% | +369,900.01% | +369,900.00% | +369,900.01% | -94.71% | -99.43% | -99.79% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
12.59
DCF (Unlevered)
0.13
-99.0%
DCF (Levered)
0.31
-97.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-56.07
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+97.1% ★ Q1'26: +97.2% (vs Q1'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +106.8% (vs Q1'23)
-
Share dilution Biotechnology: -3.4%+470.0% Q1'26: +2,125.4% (vs Q1'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: 0.00× (vs Q1'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est.
|
—
est.
|
—
|
—
— – —
|
173.81M
173.81M – 173.81M
|
| EBITDA |
-33.72M
|
—
est.
|
—
est.
|
-6.44M
|
—
— – —
|
—
— – —
|
| EBIT |
-34.42M
|
—
est.
|
—
est.
|
-6.44M
|
—
— – —
|
—
— – —
|
| Net Income |
-36.07M
est: -36.05M (0.0%)
|
-17.14M
est.
|
-16.01M
est.
|
-6.00M
est: -82.11M (+92.7%)
|
-99.27M
-99.27M – -99.27M
-20.9% YoY
|
166.94M
166.94M – 166.94M
+268.2% YoY
|
| SGA |
10.00M
|
—
est.
|
—
est.
|
3.38M
|
—
— – —
|
—
— – —
|
| EPS |
-183.15
est: -16.64 (-1,000.7%)
|
-7.91
est.
|
-7.39
est.
|
-5.39
est: -6.65 (+18.9%)
|
-8.04
-8.04 – -8.04
-20.9% YoY
|
13.52
13.52 – 13.52
+268.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-35.00M
OE per share TTM
-21.67
Owner's Yield
-196.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5,365.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
3
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Roche Finance Ltd | 5.00M | 5.80% | — | — | — | — | CO | Switzerland | 2022-02-14 | ↗ |
| 2 | Roche Holding Ltd | 5.00M | 5.80% | — | — | — | — | CO | Switzerland | 2022-02-14 | ↗ |
| 3 | Ernesto Bertarelli | 4.98M | 5.70% | — | 4.98M | — | 4.98M | IN | Delaware | 2021-06-29 | ↗ |
| 4 | Gurnet Point L.P. | 4.98M | 5.70% | — | 4.98M | — | 4.98M | PN | Delaware | 2021-06-29 | ↗ |
| 5 | Waypoint International GP LLC | 4.98M | 5.70% | — | 4.98M | — | 4.98M | OO | Delaware | 2021-06-29 | ↗ |
| 6 | Waypoint International Holdings S.A. | 4.98M | 5.70% | — | 4.98M | — | 4.98M | CO | Delaware | 2021-06-29 | ↗ |
| 7 | LSP V Management B.V. | 2.65M | 9.61% | — | 2.65M | — | 2.65M | OO | The Netherlands | 2017-12-29 | ↗ |
| 8 | Advent Life Sciences Fund II LP | 2.53M | 6.30% | — | 2.53M | — | 2.53M | PN | — | 2021-04-13 | ↗ |
| 9 | Advent Life Sciences LLP | 2.53M | 6.30% | — | 2.53M | — | 2.53M | PN | — | 2021-04-13 | ↗ |
| 10 | Kaasim Mahmood | 2.53M | 6.30% | — | 2.53M | — | 2.53M | IN | — | 2021-04-13 | ↗ |
| 11 | Rajesh Parekh | 2.53M | 6.30% | — | 2.53M | — | 2.53M | IN | — | 2021-04-13 | ↗ |
| 12 | Shahzad Malik | 2.53M | 6.30% | — | 2.53M | — | 2.53M | IN | — | 2021-04-13 | ↗ |
| 13 | Pontifax (Cayman) III, L.P. | 2.29M | 8.29% | — | 2.29M | — | 2.29M | PN | Cayman Islands | 2018-01-02 | ↗ |
| 14 | Menora Mivtachim Holdings Ltd. | 2.09M | 5.22% | — | 2.09M | — | 2.09M | CO | Israel | 2021-02-11 | ↗ |
| 15 | CEL Catalyst China Israel General Partner Limited | 1.79M | 4.99% | — | 1.79M | — | 1.79M | OO | Cayman Islands | 2019-04-29 | ↗ |
| 16 | Catalyst CEL Management Ltd. | 1.79M | 4.99% | — | 1.79M | — | 1.79M | OO | Cayman Islands | 2019-04-29 | ↗ |
| 17 | GHS Partners Limited | 1.66M | 6.01% | — | 1.66M | — | 1.66M | OO | Cayman Islands | 2017-12-29 | ↗ |
| 18 | GHS Partnership L.P. | 1.66M | 6.01% | — | 1.66M | — | 1.66M | PN | Cayman Islands | 2017-12-29 | ↗ |
| 19 | Pontifax IV GP L.P. | 1.59M | 5.75% | — | 1.59M | — | 1.59M | PN | Israel | 2017-12-29 | ↗ |
| 20 | CEL CATALYST China Israel Fund L.P. | 1.57M | 4.37% | — | 1.57M | — | 1.57M | PN | Cayman Islands | 2019-04-29 | ↗ |
| 21 | Pontifax (Israel) IV, L.P. | 783.7K | 2.84% | — | 783.7K | — | 783.7K | PN | Israel | 2018-01-02 | ↗ |
| 22 | BARCLAYS GLOBAL INVESTORS, NA. | 433.0K | 2.25% | — | — | — | — | BK | Liechtenstein | 2018-07-26 | ↗ |
| 23 | Pontifax (China) IV L.P. | 423.7K | 1.53% | — | 423.7K | — | 423.7K | PN | Cayman Islands | 2018-01-02 | ↗ |
| 24 | Pontifax (Cayman) IV L.P. | 381.5K | 1.38% | — | 381.5K | — | 381.5K | PN | Cayman Islands | 2017-12-29 | ↗ |
| 25 | Catalyst CEL Fund L.P. | 224.3K | 0.62% | — | 224.3K | — | 224.3K | PN | Cayman Islands | 2019-04-29 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
201.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+201,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Coastlands Capital LP | 10% Owner | J-Other | A | Pre-funded Warrant | 1,250,000 | 0.01 | 12.5K | 30,612,243 | I | ↗ |
| 2026-04-28 | Domicilium Real Estate Fund III LP | 10% Owner | — | — | Common Stock, $0.01 par value | 0 | 0.00 | — | 1,250,000 | I | ↗ |
| 2026-04-27 | Coastlands Capital LP | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,250,000 | I | ↗ |
| 2026-02-28 | Aggarwal Sumit | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 260,946 | 0.15 | 39.1K | 3,336,144 | D | ↗ |
| 2026-01-24 | Walts Alan Edmund | Director | M-Exempt | D | Restricted Stock Units | 1,875 | 0.00 | — | 1,875 | D | ↗ |
| 2026-01-24 | Rubin Steven D | Director | M-Exempt | A | Common Stock | 1,875 | 0.00 | — | 14,625 | D | ↗ |
| 2026-01-24 | Aggarwal Sumit | Director / Officer / 10% Owner | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-09-19 | Walts Alan Edmund | Director | A-Award | A | Stock Option (Right to Buy) | 395,680 | 0.15 | 59.4K | 395,680 | D | ↗ |
| 2025-09-19 | Rubin Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 179,854 | 0.15 | 27.0K | 179,854 | D | ↗ |
| 2025-09-19 | Aggarwal Sumit | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,396,810 | D | ↗ |
| 2025-08-14 | Aggarwal Sumit | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 196,880 | 0.00 | 19.69 | 396,810 | D | ↗ |
| 2025-01-24 | Walts Alan Edmund | Director | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 16,692 | D | ↗ |
| 2025-01-24 | Rubin Steven D | Director | M-Exempt | D | Restricted Stock Units | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2025-01-24 | Androski Lindsay | Director | M-Exempt | D | Restricted Stock Units | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2025-01-24 | Aggarwal Sumit | Director | M-Exempt | D | Restricted Stock Units | 30,000 | 0.00 | — | 30,000 | D | ↗ |
| 2024-10-16 | Walts Alan Edmund | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 12,942 | D | ↗ |
| 2024-10-16 | Rubin Steven D | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 12,000 | D | ↗ |
| 2024-10-16 | Androski Lindsay | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 12,000 | D | ↗ |
| 2024-10-16 | Aggarwal Sumit | Director / Officer / 10% Owner | D-Return | D | Stock Option (Right to Buy) | 24,810 | 1.41 | 35.0K | 0 | D | ↗ |
| 2024-01-24 | Walts Alan Edmund | Director | A-Award | A | Restricted Stock Units | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2024-01-24 | Rubin Steven D | Director | A-Award | A | Restricted Stock Units | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2024-01-24 | Androski Lindsay | Director | A-Award | A | Restricted Stock Units | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2024-01-24 | Aggarwal Sumit | Director / Officer | A-Award | A | Restricted Stock Units | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2023-01-30 | Walts Alan Edmund | Director | A-Award | A | Stock Options (Right to Buy) | 2,859 | 4.00 | 11.4K | 2,859 | — | ↗ |
| 2023-01-30 | Rubin Steven D | Director | A-Award | A | Stock Options (Right to Buy) | 2,859 | 4.00 | 11.4K | 2,859 | — | ↗ |
| 2023-01-30 | Kariv Tomer | Director | A-Award | A | Stock Options (Right to Buy) | 2,859 | 4.00 | 11.4K | 2,859 | — | ↗ |
| 2023-01-30 | Androski Lindsay | Director | A-Award | A | Stock Options (Right to Buy) | 2,859 | 4.00 | 11.4K | 2,859 | — | ↗ |
| 2023-01-25 | MODUR VIJAY | Officer | A-Award | A | Stock Options (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-25 | Aggarwal Sumit | Officer | A-Award | A | Stock Options (Right to Buy) | 68,700 | 0.00 | — | 68,700 | — | ↗ |
| 2022-07-01 | Androski Lindsay | Director | A-Award | A | Stock Options (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-15 | Walts Alan Edmund | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Veinrib Gadi | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Seehra Jasbir | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Rubin Steven D | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | PAREKH RAJESH B | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Nussbaum Ran | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Kariv Tomer | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Avnur Zafrira | Director | A-Award | A | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-02-06 | Aggarwal Sumit | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 42,790 | 18.40 | 787.3K | 42,790 | D | ↗ |
| 2021-12-01 | Walts Alan Edmund | Director | M-Exempt | D | Restricted Stock Units | 37,695 | 0.00 | — | 0 | — | ↗ |
| 2021-12-01 | MODUR VIJAY | Officer | M-Exempt | D | Restricted Stock Units | 219,326 | 0.00 | — | 0 | — | ↗ |
| 2021-12-01 | Aggarwal Sumit | Director / Officer | F-InKind | D | Common Stock | 81,933 | 0.72 | 59.0K | 197,225 | — | ↗ |
| 2021-11-29 | Geffken Daniel E. | Officer | P-Purchase | A | Common Stock | 50,000 | 0.72 | 36.0K | 50,000 | — | ↗ |
| 2021-07-30 | Belloff Neil S. | Officer | M-Exempt | A | Common Stock | 1,563 | 0.00 | — | 33,158 | — | ↗ |
| 2021-05-25 | Belloff Neil S. | Officer | M-Exempt | D | Restricted Stock Units | 6,250 | 0.00 | — | 68,750 | — | ↗ |
| 2021-05-19 | Walts Alan Edmund | Director | A-Award | A | Stock Option (Right to Buy) | 3,334 | 1.48 | 4.9K | 3,334 | — | ↗ |
| 2021-05-19 | Veinrib Gadi | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-05-19 | Seehra Jasbir | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-05-19 | Rubin Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-05-19 | PAREKH RAJESH B | Director | A-Award | A | Stock Option (Right to Buy) | 3,334 | 0.00 | — | 3,334 | — | ↗ |
| 2021-05-19 | Nussbaum Ran | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-05-19 | Kariv Tomer | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-05-19 | Avnur Zafrira | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-05-18 | MODUR VIJAY | Officer | A-Award | A | Stock Options (Right to Buy) | 496,204 | 1.41 | 699.6K | 496,204 | — | ↗ |
| 2021-05-18 | Aggarwal Sumit | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 992,409 | 1.41 | 1.40M | 992,409 | — | ↗ |
| 2021-05-13 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | P-Purchase | A | Common Stock | 592,592 | 1.35 | 800.0K | 616,592 | — | ↗ |
| 2021-05-13 | PAREKH RAJESH B | Director | P-Purchase | A | Common Stock | 84,776 | 1.35 | 114.4K | 171,807 | — | ↗ |
| 2021-05-13 | Nussbaum Ran | Director | P-Purchase | A | Common Stock | 2,630,487 | 1.35 | 3.55M | 3,679,797 | — | ↗ |
| 2021-05-13 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 592,592 | 1.35 | 800.0K | 616,592 | — | ↗ |
| 2021-04-30 | Belloff Neil S. | Officer | F-InKind | D | Common Stock | 459 | 2.18 | 1.0K | 27,180 | — | ↗ |
| 2021-04-20 | Geffken Daniel E. | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 100,000 | 2.38 | 238.0K | 100,000 | — | ↗ |
| 2021-04-01 | Walts Alan Edmund | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-01 | PAREKH RAJESH B | Director | A-Award | A | Common Stock | 2,445,239 | 0.00 | — | 2,445,239 | — | ↗ |
| 2021-04-01 | MODUR VIJAY | Officer | A-Award | A | Stock Options (Right to Buy) | 711,619 | 3.36 | 2.39M | 711,619 | — | ↗ |
| 2021-04-01 | Geffken Daniel E. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-01 | Aggarwal Sumit | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-24 | Rakers Gary D. | Officer | — | D | Employee Stock Option (Right to Buy) | 7,200 | 4.57 | 32.9K | 0 | — | ↗ |
| 2021-02-25 | Williams Gregory C. | Director / Officer | M-Exempt | D | Restricted Stock Units | 50,000 | 0.00 | — | 150,000 | — | ↗ |
| 2021-02-25 | Belloff Neil S. | Officer | M-Exempt | A | Common Stock | 25,000 | 0.00 | — | 33,415 | — | ↗ |
| 2021-02-12 | Williams Gregory C. | Director / Officer | A-Award | A | Stock Options | 300,000 | 4.04 | 1.21M | 300,000 | — | ↗ |
| 2021-02-12 | MacDonald Stephen G. | Officer | A-Award | A | Stock Options | 18,849 | 4.04 | 76.1K | 18,849 | — | ↗ |
| 2021-02-12 | Belloff Neil S. | Officer | A-Award | A | Stock Options | 120,000 | 4.04 | 484.8K | 120,000 | — | ↗ |
| 2021-01-30 | Williams Gregory C. | Director / Officer | F-InKind | D | Common Stock | 643 | 3.44 | 2.2K | 9,989 | — | ↗ |
| 2021-01-30 | Belloff Neil S. | Officer | F-InKind | D | Common Stock | 542 | 3.44 | 1.9K | 8,415 | — | ↗ |
| 2020-10-30 | Williams Gregory C. | Director / Officer | M-Exempt | D | Restricted Stock Units | 1,875 | 0.00 | — | 16,875 | — | ↗ |
| 2020-10-30 | Belloff Neil S. | Officer | M-Exempt | D | Restricted Stock Units | 1,562 | 0.00 | — | 14,063 | — | ↗ |
| 2020-07-30 | Williams Gregory C. | Director / Officer | F-InKind | D | Common Stock | 576 | 2.84 | 1.6K | 7,507 | — | ↗ |
| 2020-07-30 | Belloff Neil S. | Officer | M-Exempt | A | Common Stock | 1,563 | 0.00 | — | 6,750 | — | ↗ |
| 2020-05-20 | Veinrib Gadi | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Seehra Jasbir | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Rubin Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Nussbaum Ran | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Noiman Silvia | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Kleijwegt Martijn | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Kariv Tomer | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-05-20 | Avnur Zafrira | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.39 | 67.8K | 20,000 | — | ↗ |
| 2020-04-30 | Williams Gregory C. | Director / Officer | M-Exempt | A | Common Stock | 1,875 | 0.00 | — | 6,785 | — | ↗ |
| 2020-04-30 | Belloff Neil S. | Officer | F-InKind | D | Common Stock | 459 | 2.92 | 1.3K | 5,187 | — | ↗ |
| 2020-03-15 | WEAVER GREGORY L | — | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 11,517 | — | ↗ |
| 2020-02-29 | Ward Robert | — | M-Exempt | D | Restricted Stock Units | 5,607 | 0.00 | — | 0 | — | ↗ |
| 2020-02-29 | Snow David P. | — | M-Exempt | A | Common Stock | 4,688 | 0.00 | — | 8,893 | — | ↗ |
| 2020-02-25 | Williams Gregory C. | Director / Officer | A-Award | A | Restricted Stock Units | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2020-02-25 | Belloff Neil S. | Officer | A-Award | A | Stock Options | 200,000 | 3.59 | 718.0K | 200,000 | — | ↗ |
| 2020-02-24 | MacDonald Stephen G. | Officer | — | D | Employee Stock Option (Right to Buy) | 15,000 | 3.93 | 59.0K | 0 | — | ↗ |
| 2020-01-30 | Williams Gregory C. | Officer | M-Exempt | A | Restricted Stock Units | 7,500 | 0.00 | — | 22,500 | D | ↗ |
| 2020-01-30 | WEAVER GREGORY L | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 9,500 | D | ↗ |
| 2020-01-30 | Snow David P. | Officer | M-Exempt | A | Restricted Stock Units | 6,250 | 0.00 | — | 18,750 | D | ↗ |
| 2020-01-30 | Belloff Neil S. | Officer | M-Exempt | D | Restricted Stock Units | 6,250 | 0.00 | — | 18,750 | D | ↗ |
| 2019-12-26 | Ward Robert | Director / Officer | F-InKind | D | Common Stock | 15,806 | 7.26 | 114.8K | 190,746 | — | ↗ |
| 2019-09-26 | Ward Robert | Director / Officer | F-InKind | D | Common Stock | 10,467 | 4.37 | 45.7K | 170,953 | — | ↗ |
| 2019-09-12 | Williams Gregory C. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 225,000 | 6.47 | 1.46M | 225,000 | — | ↗ |
| 2019-09-12 | Snow David P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 6.47 | 970.5K | 150,000 | — | ↗ |
| 2019-09-12 | Belloff Neil S. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 6.47 | 647.0K | 100,000 | — | ↗ |
| 2019-06-26 | Ward Robert | Director / Officer | M-Exempt | D | Restricted Stock Units | 35,599 | 0.00 | — | 355,992 | — | ↗ |
| 2019-06-24 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | P-Purchase | A | Common Stock | 46,933 | 9.00 | 422.4K | 567,329 | — | ↗ |
| 2019-06-24 | Nussbaum Ran | Director | P-Purchase | A | Common Stock | 24,000 | 9.00 | 216.0K | 24,000 | — | ↗ |
| 2019-06-24 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 42,261 | 9.00 | 380.3K | 510,846 | — | ↗ |
| 2019-05-29 | Veinrib Gadi | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Seehra Jasbir | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Rubin Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Nussbaum Ran | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Noiman Silvia | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Kleijwegt Martijn | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Kariv Tomer | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-05-29 | Avnur Zafrira | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.02 | 180.4K | 20,000 | — | ↗ |
| 2019-03-26 | Ward Robert | Director / Officer | M-Exempt | D | Restricted Stock Units | 35,599 | 0.00 | — | 391,591 | — | ↗ |
| 2019-01-30 | Williams Gregory C. | Officer | A-Award | A | Restricted Stock Units | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2019-01-30 | Ward Robert | Director / Officer | A-Award | A | Stock Options | 226,000 | 11.53 | 2.61M | 226,000 | — | ↗ |
| 2019-01-30 | WEAVER GREGORY L | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2019-01-30 | Snow David P. | Officer | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2019-01-30 | Belloff Neil S. | Officer | A-Award | A | Stock Options | 50,000 | 11.53 | 576.5K | 50,000 | — | ↗ |
| 2018-12-28 | Ward Robert | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 95,557 | — | ↗ |
| 2018-12-26 | Ward Robert | Director / Officer | M-Exempt | A | Common Stock | 213,595 | 0.00 | — | 228,595 | — | ↗ |
| 2018-06-25 | Williams Gregory C. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 18.84 | 5.65M | 300,000 | — | ↗ |
| 2018-06-25 | Snow David P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 18.85 | 3.77M | 200,000 | — | ↗ |
| 2018-06-18 | Belloff Neil S. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 20.85 | 2.61M | 125,000 | — | ↗ |
| 2018-06-15 | Veinrib Gadi | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Seehra Jasbir | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Rubin Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Pontifax Management III G.P. (2011) Ltd. | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Nussbaum Ran | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Noiman Silvia | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Kleijwegt Martijn | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Kariv Tomer | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-15 | Avnur Zafrira | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 23.27 | 930.8K | 40,000 | — | ↗ |
| 2018-06-06 | Noiman Silvia | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 349,400 | 0.00 | 209.64 | 0 | — | ↗ |
| 2018-05-22 | Ward Robert | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 14.34 | 71.7K | 15,000 | — | ↗ |
| 2018-05-16 | Huertas Pedro | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 137,725 | — | ↗ |
| 2018-05-11 | Huertas Pedro | Officer | A-Award | A | Common Stock | 104,725 | 0.00 | — | 104,725 | — | ↗ |
| 2018-05-10 | Huertas Pedro | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 104,725 | 14.88 | 1.56M | 104,725 | — | ↗ |
| 2018-04-30 | Shabtai Gilad | 10% Owner | P-Purchase | A | Common Stock | 75,000 | 9.75 | 731.3K | 3,351,770 | — | ↗ |
| 2018-04-30 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | P-Purchase | A | Common Stock | 172,626 | 9.75 | 1.68M | 962,504 | — | ↗ |
| 2018-04-30 | Nussbaum Ran | Director | P-Purchase | A | Common Stock | 93,333 | 9.75 | 910.0K | 520,396 | — | ↗ |
| 2018-04-30 | Kleijwegt Martijn | Director | P-Purchase | A | Common Stock | 300,000 | 9.75 | 2.93M | 2,953,673 | — | ↗ |
| 2018-04-30 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 172,626 | 9.75 | 1.68M | 962,504 | — | ↗ |
| 2018-04-04 | Shabtai Gilad | 10% Owner | P-Purchase | A | Common Stock | 2,600 | 9.58 | 24.9K | 3,276,770 | — | ↗ |
| 2018-04-03 | Shabtai Gilad | 10% Owner | P-Purchase | A | Common Stock | 5,700 | 9.41 | 53.6K | 3,274,170 | — | ↗ |
| 2018-03-29 | Shabtai Gilad | 10% Owner | P-Purchase | A | Common Stock | 4,500 | 9.64 | 43.4K | 3,268,470 | — | ↗ |
| 2018-03-26 | Avnur Zafrira | Director | P-Purchase | A | Common Stock | 2,000 | 9.49 | 19.0K | 2,263 | — | ↗ |
| 2018-03-23 | Ward Robert | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 8.99 | 89.9K | 10,000 | — | ↗ |
| 2018-03-23 | WEAVER GREGORY L | Officer | P-Purchase | A | Common Stock | 4,500 | 8.56 | 38.5K | 4,500 | — | ↗ |
| 2018-03-22 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | P-Purchase | A | Common Stock | 1,600 | 8.00 | 12.8K | 427,063 | — | ↗ |
| 2018-03-22 | Nussbaum Ran | Director | P-Purchase | A | Common Stock | 1,441 | 8.00 | 11.5K | 384,544 | — | ↗ |
| 2018-03-22 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 1,600 | 8.00 | 12.8K | 427,063 | — | ↗ |
| 2018-03-21 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | P-Purchase | A | Common Stock | 1,585 | 7.55 | 12.0K | 383,103 | — | ↗ |
| 2018-03-21 | Nussbaum Ran | Director | P-Purchase | A | Common Stock | 1,585 | 7.55 | 12.0K | 383,103 | — | ↗ |
| 2018-03-21 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 1,585 | 7.55 | 12.0K | 383,103 | — | ↗ |
| 2018-03-21 | Avnur Zafrira | Director | P-Purchase | A | Common Stock | 263 | 7.60 | 2.0K | 263 | — | ↗ |
| 2018-02-26 | Seehra Jasbir | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-15 | Huertas Pedro | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 6.65 | 332.5K | 50,000 | — | ↗ |
| 2017-12-26 | Ward Robert | Director / Officer | A-Award | D | Stock Options (Right to Buy) | 22,427 | 8.00 | 179.4K | 22,427 | — | ↗ |
| 2017-12-20 | WEAVER GREGORY L | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-20 | Huertas Pedro | Officer | — | D | Stock Option (Right to Buy) | 14,395 | 0.96 | 13.8K | 0 | — | ↗ |
| 2017-12-19 | Veinrib Gadi | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-19 | Shabtai Gilad | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,263,970 | — | ↗ |
| 2017-12-19 | Rubin Steven D | Director | A-Award | A | Common Stock Option (Right to Buy) | 43,189 | 6.00 | 259.1K | 43,189 | — | ↗ |
| 2017-12-19 | RECTOR DAVID | — | A-Award | A | Common Stock Option (Right to Buy) | 27,500 | 6.00 | 165.0K | 27,500 | — | ↗ |
| 2017-12-19 | Pontifax Management III G.P. (2011) Ltd. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,287,937 | — | ↗ |
| 2017-12-19 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 783,664 | — | ↗ |
| 2017-12-19 | Opko Health, Inc. | 10% Owner | A-Award | A | Common Stock | 495,126 | 0.00 | — | 1,289,818 | — | ↗ |
| 2017-12-19 | Nussbaum Ran | Director | — | I | Common Stock | 0 | 0.00 | — | 4,900,249 | — | ↗ |
| 2017-12-19 | Noiman Silvia | Director / Officer | — | D | Stock Option (Right to Buy) | 69,880 | 1.00 | 69.9K | 0 | — | ↗ |
| 2017-12-19 | Kleijwegt Martijn | Director | — | I | Common Stock | 0 | 0.00 | — | 2,653,673 | — | ↗ |
| 2017-12-19 | Kariv Tomer | Director | — | I | Common Stock | 0 | 0.00 | — | 423,703 | — | ↗ |
| 2017-12-19 | Heft Robert | Director | — | D | Stock Option (Right to Buy) | 291,499 | 0.96 | 279.8K | 0 | — | ↗ |
| 2017-12-19 | FROST PHILLIP MD ET AL | — | A-Award | A | Company Stock Option | 3,621 | 6.00 | 21.7K | 3,621 | — | ↗ |
| 2017-12-19 | BRACA JOHN N | — | A-Award | A | Company Stock Option | 18,190 | 6.00 | 109.1K | 18,190 | — | ↗ |
| 2017-12-19 | Avnur Zafrira | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-19 | Opko Health, Inc. | 10% Owner | C-Conversion | D | 0% Series C Convertible Perferred | 66,667 | 0.40 | 26.7K | 0 | — | ↗ |
| 2017-08-10 | Opko Health, Inc. | 10% Owner | C-Conversion | A | Common Stock | 2,563,699 | 0.10 | 256.4K | 14,643,838 | — | ↗ |
| 2017-07-28 | Opko Health, Inc. | 10% Owner | — | D | 0% Series C Convertible Perferred | 1,250,007 | 0.40 | 500.0K | 0 | — | ↗ |
| 2017-02-14 | Rubin Steven D | Director | A-Award | A | Company Stock Option | 160,227 | 0.22 | 35.2K | 160,227 | — | ↗ |
| 2017-02-14 | FROST PHILLIP MD ET AL | Director | A-Award | A | Company Stock Option | 109,091 | 0.22 | 24.0K | 109,091 | — | ↗ |
| 2017-02-14 | BRACA JOHN N | Director | A-Award | A | Company Stock Option | 167,045 | 0.22 | 36.7K | 167,045 | — | ↗ |
| 2016-11-10 | Opko Health, Inc. | 10% Owner | — | D | Convertible Promissory Note | 1,500,000 | 0.10 | 150.0K | 0 | — | ↗ |
| 2016-06-13 | Rubin Steven D | Director | A-Award | A | Company Stock Option | 89,773 | 0.22 | 19.8K | 89,773 | — | ↗ |
| 2016-06-13 | FROST PHILLIP MD ET AL | Director / 10% Owner | A-Award | A | Company Stock Option | 78,409 | 0.22 | 17.2K | 78,409 | — | ↗ |
| 2016-06-13 | BRACA JOHN N | Director | A-Award | A | Company Stock Option | 89,773 | 0.22 | 19.8K | 89,773 | — | ↗ |
| 2015-11-19 | Waksal Harlan | Director | A-Award | A | Company Stock Option | 40,000 | 0.50 | 20.0K | 40,000 | — | ↗ |
| 2015-11-19 | Rubin Steven D | Director | A-Award | A | Company Stock Option | 40,000 | 0.50 | 20.0K | 40,000 | — | ↗ |
| 2015-11-19 | FROST PHILLIP MD ET AL | Director / 10% Owner | A-Award | A | Company Stock Option | 32,500 | 0.50 | 16.3K | 32,500 | — | ↗ |
| 2015-11-19 | BRACA JOHN N | Director | A-Award | A | Company Stock Option | 42,500 | 0.50 | 21.3K | 42,500 | — | ↗ |
| 2015-09-29 | FROST PHILLIP MD ET AL | Director / 10% Owner | P-Purchase | A | Common Stock | 35,000 | 0.61 | 21.4K | 1,598,170 | — | ↗ |
| 2015-07-27 | Opko Health, Inc. | 10% Owner | — | D | Warrant (Right to Buy) | 333,333 | 1.50 | 500.0K | 0 | — | ↗ |
| 2015-05-18 | Waksal Harlan | Director | A-Award | A | Common Stock Option | 11,340 | 0.97 | 11.0K | 147,693 | — | ↗ |
| 2015-02-19 | Waksal Harlan | Director | A-Award | A | Common Stock Option | 26,552 | 0.54 | 14.3K | 136,353 | — | ↗ |
| 2014-11-18 | Waksal Harlan | Director | A-Award | A | Common Stock Option (right to buy) | 17,168 | 0.83 | 14.2K | 109,500 | — | ↗ |
Executive team
Top executives
Shares Outstanding
3.30M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Sumit Aggarwal Chief Executive Officer | 575.1K | — | — | 556.3K | 253.0K | 11.6K | 1.40M | 39.85% | ↗ |
| 2 | 2022 | Daniel E. Geffken Interim Chief Financial Officer | — | — | — | — | — | 64.0K | 64.0K | 0.00% | ↗ |
| 3 | 2022 | Vijay Modur Head of Research and Development | 459.9K | — | — | 243.8K | 44.1K | 11.6K | 59.3K | 410.73% | ↗ |
| 4 | 2021 | Sumit Aggarwal Chief Executive Officer | 407.7K | — | 938.0K | 4.01M | 331.3K | — | 5.69M | 87.01% | ↗ |
| 5 | 2021 | Vijay Modur Head of Research and Development | 326.9K | — | 736.9K | 2.01M | 212.5K | — | 3.28M | 83.56% | ↗ |
| 6 | 2021 | Gregory C. Williams Former Chief Executive Officer | 347.4K | — | — | 783.0K | — | 571.4K | 1.70M | 46.03% | ↗ |
| 7 | 2021 | Neil S. Belloff, Esq. Former Chief Operating Officer, General Counsel, and Corporate Secretary | 293.0K | 261.1K | — | 313.2K | — | 478.1K | 1.35M | 23.28% | ↗ |
| 8 | 2021 | Stephen G. MacDonald Former Vice President of Finance and Accounting, Treasurer | 62.2K | 67.3K | — | — | — | 10.7K | 147.3K | 0.00% | ↗ |
| 9 | 2021 | Daniel E. Geffken Interim Chief Financial Officer | — | — | — | — | — | 130.8K | 130.8K | 0.00% | ↗ |
| 10 | 2020 | Gregory C. Williams Former Chief Executive Officer | 454.6K | — | 718.0K | 916.0K | 142.5K | 13.8K | 2.25M | 72.47% | ↗ |
| 11 | 2020 | Neil S. Belloff, Esq. Chief Operating Officer, General Counsel and Corporate Secretary | 411.5K | — | 359.0K | 458.0K | 100.8K | 105.6K | 1.43M | 56.94% | ↗ |
| 12 | 2020 | Neil S. Belloff, Esq. Former Chief Operating Officer, General Counsel, and Corporate Secretary | 411.5K | — | 359.0K | 458.0K | 100.8K | 105.6K | 1.43M | 56.94% | ↗ |
| 13 | 2020 | Robert E. Ward Former Chief Executive Officer | 83.3K | — | — | — | — | 499.2K | 582.6K | 0.00% | ↗ |
| 14 | 2020 | Stephen G. MacDonald Former Vice President of Finance and Accounting, Treasurer | 276.3K | — | — | 63.2K | 67.3K | 24.8K | 431.5K | 14.64% | ↗ |
| 15 | 2020 | Stephen G. MacDonald Vice President of Finance and Accounting, Treasurer | 276.3K | — | — | 63.2K | 67.3K | 24.8K | 431.5K | 14.64% | ↗ |
| 16 | 2019 | Gregory C. Williams Chief Operating Officer | 409.4K | — | 345.9K | 1.76M | 165.0K | 12.3K | 2.69M | 78.20% | ↗ |
| 17 | 2019 | Robert E. Ward Chief Executive Officer | 500.0K | — | — | 1.77M | 200.0K | 47.4K | 2.52M | 70.33% | ↗ |
| 18 | 2019 | Robert E. Ward Former Chief Executive Officer | 500.0K | — | — | 1.77M | 200.0K | 47.4K | 2.52M | 70.33% | ↗ |
| 19 | 2019 | David P. Snow Chief Business Officer | 388.8K | — | 288.3K | 1.08M | 78.0K | 48.5K | 1.88M | 72.65% | ↗ |
| 20 | 2019 | Neil S. Belloff, Esq. Chief Operating Officer, General Counsel and Corporate Secretary | 367.1K | — | 288.3K | 825.0K | 147.7K | 46.2K | 1.67M | 66.49% | ↗ |
| 21 | 2019 | Gregory Weaver Chief Financial Officer | 357.7K | — | 230.6K | 470.4K | 71.8K | 46.5K | 1.18M | 59.56% | ↗ |
| 22 | 2019 | Stephen G. MacDonald Vice President of Finance and Accounting, Treasurer | 50.5K | 15.0K | — | 39.8K | — | 2.5K | 107.7K | 36.90% | ↗ |
| 23 | 2018 | Gregory Williams Chief Operating Officer | 244.7K | 50.0K | — | 5.66M | 78.1K | 10.5K | 6.04M | 93.65% | ↗ |
| 24 | 2018 | Gregory C. Williams Chief Operating Officer | 244.7K | 50.0K | — | 4.30M | 78.1K | 10.5K | 4.68M | 91.81% | ↗ |
| 25 | 2018 | David P. Snow Chief Business Officer | 197.5K | — | — | 2.87M | 78.1K | 83.0K | 3.22M | 88.88% | ↗ |
| 26 | 2018 | Robert E. Ward Chief Executive Officer | 452.9K | — | — | — | 425.0K | 25.8K | 903.6K | 0.00% | ↗ |
| 27 | 2018 | Gregory Weaver Chief Financial Officer | 347.2K | — | — | — | 138.0K | 37.0K | 522.2K | 0.00% | ↗ |
| 28 | 2017 | Robert E. Ward Chief Executive Officer | 6.9K | — | 5.31M | 3.43M | — | — | 8.74M | 99.92% | ↗ |
| 29 | 2017 | Gregory Weaver Chief Financial Officer | 2.8K | — | — | 1.57M | — | 19.00 | 1.57M | 99.82% | ↗ |
| 30 | 2017 | Pedro Huertas, MD, Ph.D. Chief Medical Officer | 9.3K | 3.1K | — | — | — | 1.4K | 13.8K | 0.00% | ↗ |
| 31 | 2017 | Dr. Silvia Noiman, Ph.D., MBA Former Chief Executive Officer | 4.1K | 1.1K | — | — | — | — | 5.2K | 0.00% | ↗ |
| 32 | 2014 | Ronald A. Martell (Chief Executive Officer) | — | — | — | 775.2K | — | — | 775.2K | 100.00% | ↗ |
| 33 | 2014 | Leslie J. Browne, Ph.D. (President and Chief Executive Officer) | 273.9K | — | — | 74.1K | — | — | 347.9K | 21.29% | ↗ |
| 34 | 2014 | Joel Brooks (Chief Financial Officer , Secretary and Treasurer) | 178.0K | — | — | 42.4K | — | — | 220.4K | 19.22% | ↗ |
| 35 | 2014 | Vaughn Smider, M.D., Ph.D. Chief Scientific Officer | 23.1K | — | — | — | — | — | 23.1K | 0.00% | ↗ |
| 36 | 2013 | Leslie J. Browne, Ph.D. (President and Chief Executive Officer) | 273.9K | — | — | 180.2K | — | — | 454.0K | 39.68% | ↗ |
| 37 | 2013 | Joel Brooks (Chief Financial Officer, Secretary and Treasurer) | 178.0K | — | — | 103.0K | — | — | 281.0K | 36.64% | ↗ |
| 38 | 2013 | Joel Brooks (Chief Financial Officer , Secretary and Treasurer) | 178.0K | — | — | 103.0K | — | — | 281.0K | 36.64% | ↗ |
| 39 | 2013 | Richard Dondero (Vice-President of Research and Development) | 161.0K | — | — | 103.0K | — | — | 264.0K | 39.00% | ↗ |
| 40 | 2013 | John E. Thompson Ph.D. (Executive Vice- President and Chief Scientific Officer) | 67.5K | — | — | 103.0K | — | — | 170.5K | 60.40% | ↗ |
| 41 | 2012 | Leslie J. Browne, Ph.D. (President and Chief Executive Officer) | 266.3K | — | — | 151.5K | — | 9.8K | 427.6K | 35.43% | ↗ |
| 42 | 2012 | Joel Brooks (Chief Financial Officer , Secretary and Treasurer) | 172.7K | — | — | 86.6K | — | — | 259.3K | 33.39% | ↗ |
| 43 | 2012 | Joel Brooks (Chief Financial Officer, Secretary and Treasurer) | 172.7K | — | — | 86.6K | — | — | 259.3K | 33.39% | ↗ |
| 44 | 2012 | John E. Thompson Ph.D. (Executive Vice-President and Chief Scientific Officer) | 166.0K | — | — | 90.5K | — | — | 259.1K | 34.94% | ↗ |
| 45 | 2012 | Richard Dondero (Vice-President of Research and Development) | 155.8K | — | — | 86.6K | — | — | 242.4K | 35.72% | ↗ |
| 46 | 2012 | John E. Thompson Ph.D. (Executive Vice- President and Chief Scientific Officer) | 67.5K | — | — | 86.6K | — | — | 154.1K | 56.19% | ↗ |
| 47 | 2011 | Leslie J. Browne, Ph.D. (President and Chief Executive Officer) | 250.5K | — | — | 154.4K | — | — | 404.9K | 38.14% | ↗ |
| 48 | 2011 | Richard Dondero (Vice-President of Research) | 172.7K | — | — | 86.6K | — | — | 259.3K | 33.39% | ↗ |
| 49 | 2011 | Joel Brooks (Chief Financial Officer, Secretary and Treasurer) | 166.0K | — | 2.6K | 90.5K | — | — | 259.1K | 35.94% | ↗ |
| 50 | 2011 | Richard Dondero (Vice-President of Research and Development) | 148.8K | — | — | 90.5K | — | — | 239.4K | 37.82% | ↗ |
| 51 | 2011 | John E. Thompson Ph.D. (Executive Vice- President and Chief Scientific Officer) | 65.0K | — | — | 90.5K | — | — | 155.5K | 58.21% | ↗ |
| 52 | 2011 | Joel Brooks (Chief Financial Officer , Secretary and Treasurer) | 27.9K | — | — | — | — | — | 27.9K | 0.00% | ↗ |
| 53 | 2010 | Joel Brooks (Chief Financial Officer , Secretary and Treasurer) | 27.9K | 15.0K | 2.6K | 440.0K | — | — | 467.9K | 94.60% | ↗ |
| 54 | 2010 | Leslie J. Browne, Ph.D. (President and Chief Executive Officer) | 250.5K | — | — | — | — | — | 404.9K | 0.00% | ↗ |
| 55 | 2010 | John E. Thompson Ph.D. (Executive Vice-President and Chief Scientific Officer) | 163.3K | — | — | 66.0K | — | — | 244.3K | 27.02% | ↗ |
| 56 | 2010 | Joel P. Brooks (Chief Financial Officer , Secretary and Treasurer) | 163.3K | 15.0K | — | 66.0K | — | — | 244.3K | 27.02% | ↗ |
| 57 | 2010 | Bruce C. Galton (Former President and Chief Executive Officer) | 91.6K | — | — | — | — | 97.9K | 189.5K | 0.00% | ↗ |
| 58 | 2010 | Sascha P. Fedyszyn (Former Vice-President of Corporate Development and Secretary) | 56.4K | — | — | — | — | 42.7K | 99.1K | 0.00% | ↗ |
| 59 | 2010 | Jack Van Hulst (Former President and Chief Executive Officer) | 32.5K | — | — | 38.6K | — | — | 74.5K | 51.84% | ↗ |
| 60 | 2010 | Richard Dondero (Vice-President of Research) | — | 15.0K | — | — | — | — | 15.0K | 0.00% | ↗ |
| 61 | 2009 | Leslie J. Browne, Ph.D. (President and Chief Executive Officer) | — | — | — | 440.0K | — | — | 467.9K | 94.04% | ↗ |
| 62 | 2009 | Bruce C. Galton (Former President and Chief Executive Officer) | 258.3K | — | 39.6K | — | — | — | 297.9K | 13.29% | ↗ |
| 63 | 2009 | Bruce C. Galton (President and Chief Executive Officer) | 258.3K | — | 39.6K | — | — | — | 297.9K | 13.29% | ↗ |
| 64 | 2009 | Joel Brooks (Chief Financial Officer , Secretary and Treasurer) | — | — | — | 90.5K | — | — | 259.1K | 34.94% | ↗ |
| 65 | 2009 | Joel P. Brooks (Chief Financial Officer and Treasurer) | 162.0K | — | 16.8K | — | — | — | 178.8K | 9.40% | ↗ |
| 66 | 2009 | Joel P. Brooks (Chief Financial Officer , Secretary and Treasurer) | 162.0K | — | 16.8K | — | — | — | 178.8K | 9.40% | ↗ |
| 67 | 2009 | Richard Dondero (Vice-President of Research) | 163.3K | — | — | — | — | — | 163.3K | 0.00% | ↗ |
| 68 | 2009 | Sascha P. Fedyszyn (Vice-President of Corporate Development and Secretary) | 108.1K | — | 25.2K | — | — | — | 133.3K | 18.91% | ↗ |
| 69 | 2009 | Sascha P. Fedyszyn (Former Vice-President of Corporate Development and Secretary) | 108.1K | — | 25.2K | — | — | — | 133.3K | 18.91% | ↗ |
| 70 | 2009 | John E. Thompson Ph.D. (Executive Vice-President and Chief Scientific Officer) | 65.0K | — | — | 22.1K | — | — | 87.1K | 25.36% | ↗ |
| 71 | 2008 | Bruce C. Galton (President and Chief Executive Officer) | 258.3K | — | 173.5K | — | — | 14.7K | 446.5K | 38.85% | ↗ |
| 72 | 2008 | Richard Dondero (Vice-President of Research) | 130.0K | — | — | 286.4K | — | — | 416.4K | 68.78% | ↗ |
| 73 | 2008 | Bruce C. Galton (Former President and Chief Executive Officer) | 258.3K | — | 49.7K | — | — | 14.7K | 308.1K | 16.14% | ↗ |
| 74 | 2008 | John E. Thompson Ph.D. (Executive Vice-President and Chief Scientific Officer) | 65.0K | — | — | 233.1K | — | — | 298.1K | 78.19% | ↗ |
| 75 | 2008 | Joel P. Brooks (Chief Financial Officer and Treasurer) | 149.9K | — | 86.4K | — | — | — | 236.3K | 36.57% | ↗ |
| 76 | 2008 | Joel P. Brooks (Chief Financial Officer , Secretary and Treasurer) | 149.9K | — | 36.9K | — | — | — | 186.8K | 19.76% | ↗ |
| 77 | 2008 | Sascha P. Fedyszyn (Vice-President of Corporate Development and Secretary) | 103.6K | — | 74.4K | — | — | 3.7K | 181.8K | 40.95% | ↗ |
| 78 | 2008 | Sascha P. Fedyszyn (Former Vice-President of Corporate Development and Secretary) | 103.6K | — | 24.9K | — | — | 3.7K | 128.6K | 19.40% | ↗ |
| 79 | 2007 | Bruce C. Galton (President and Chief Executive Officer) | 244.7K | — | — | 34.0K | — | — | 278.7K | 12.20% | ↗ |
| 80 | 2007 | Joel P. Brooks (Chief Financial Officer and Treasurer) | 143.5K | — | — | 21.3K | — | — | 164.7K | 12.90% | ↗ |
| 81 | 2007 | Joel Brooks (Chief Financial Officer and Treasurer) | 143.5K | — | — | 21.3K | — | — | 164.7K | 12.90% | ↗ |
| 82 | 2007 | Richard Dondero (Vice-President of Research) | 124.5K | — | — | 21.3K | — | — | 145.8K | 14.58% | ↗ |
| 83 | 2007 | Sascha P. Fedyszyn (Vice-President of Corporate Development and Secretary) | 95.8K | — | — | 21.3K | — | — | 117.0K | 18.16% | ↗ |
| 84 | 2007 | John E. Thompson Ph.D. (Executive Vice-President and Chief Scientific Officer) | 63.7K | — | — | 21.3K | — | — | 85.0K | 25.01% | ↗ |
| 85 | 2006 | Bruce C. Galton President and Chief Executive Officer | 242.8K | — | — | — | — | — | 242.8K | 0.00% | ↗ |
| 86 | 2006 | Joel P. Brooks Chief Financial Officer and Treasurer | 137.7K | — | — | — | — | — | 137.7K | 0.00% | ↗ |
| 87 | 2006 | Richard Dondero Vice President of Research and Development | 118.7K | — | — | — | — | — | 118.7K | 0.00% | ↗ |
| 88 | 2006 | Sascha P. Fedyszyn Vice President of Corporate Development and Secretary | 92.3K | — | — | — | — | — | 92.3K | 0.00% | ↗ |
| 89 | 2006 | John E. Thompson, Ph.D. Executive Vice President and Chief Scientific Officer | — | — | — | — | — | 61.2K | 61.2K | 0.00% | ↗ |
| 90 | 2005 | Bruce C. Galton President and Chief Executive Officer | 240.0K | — | — | 40.0K | — | — | 280.0K | 14.28% | ↗ |
| 91 | 2005 | Joel P. Brooks Chief Financial Officer and Treasurer | 132.7K | — | — | 25.0K | — | — | 157.7K | 15.86% | ↗ |
| 92 | 2005 | Richard Dondero Vice President of Research and Development | 108.6K | — | — | 35.0K | — | — | 143.6K | 24.38% | ↗ |
| 93 | 2005 | Sascha P. Fedyszyn Vice President of Corporate Development and Secretary | 83.7K | — | — | 20.0K | — | — | 103.7K | 19.29% | ↗ |
| 94 | 2005 | John E. Thompson, Ph.D. Executive Vice President and Chief Scientific Officer | — | — | — | 20.0K | — | 60.0K | 80.0K | 25.00% | ↗ |
| 95 | 2004 | Bruce C. Galton President and Chief Executive Officer | 225.4K | — | — | 35.0K | — | — | 260.4K | 13.44% | ↗ |
| 96 | 2004 | Joel P. Brooks Chief Financial Officer and Treasurer | 126.3K | — | — | 20.0K | — | — | 146.3K | 13.67% | ↗ |
| 97 | 2004 | John E. Thompson, Ph.D. Executive Vice President and Chief Scientific Officer | — | — | — | 55.0K | — | 60.0K | 115.0K | 47.83% | ↗ |
| 98 | 2004 | Sascha P. Fedyszyn Vice President of Corporate Development and Secretary | 74.7K | — | — | 20.0K | — | — | 94.7K | 21.12% | ↗ |
| 99 | 2003 | Bruce C. Galton President and Chief Executive Officer | 201.7K | — | — | 80.0K | — | — | 281.7K | 28.40% | ↗ |
| 100 | 2003 | Joel P. Brooks Chief Financial Officer and Treasurer | 115.9K | — | — | 35.0K | — | — | 150.9K | 23.20% | ↗ |
| 101 | 2003 | Sascha P. Fedyszyn Vice President of Corporate Development and Secretary | 69.2K | — | — | 35.0K | — | — | 104.2K | 33.58% | ↗ |
| 102 | 2003 | John E. Thompson, Ph.D. Executive Vice President and Chief Scientific Officer | — | — | — | 20.0K | — | 48.0K | 68.0K | 29.41% | ↗ |
| 103 | 2002 | Bruce C. Galton President and Chief Executive Officer | 99.6K | — | — | 430.0K | — | — | 529.6K | 81.19% | ↗ |
| 104 | 2002 | Joel P. Brooks Chief Financial Officer and Treasurer | 111.0K | — | — | 12.5K | — | — | 123.5K | 10.13% | ↗ |
| 105 | 2002 | Sascha P. Fedyszyn Vice President of Corporate Development and Secretary | 66.2K | — | — | 10.0K | — | — | 76.2K | 13.12% | ↗ |
| 106 | 2002 | John E. Thompson, Ph.D. Executive Vice President and Chief Scientific Officer | — | — | — | 20.0K | — | 36.0K | 56.0K | 35.71% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sumit Aggarwal | President, Chief Executive Officer & Director | 955.8K | male |
| Daniel E. Geffken | Interim Chief Financial Officer | 4.4K | male |
| Ali Hariri | Chief Medical Officer | — | — |
| Barbara Ryan | Investor Relations Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELOX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
